RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

被引：0
|
作者：
Hatzivassiliou, Georgia
Song, Kyung
Yen, Lvana
Brandhuber, Barbara J.
Anderson, Daniel J.
Alvarado, Ryan
Ludlam, Mary Jc
Stokoe, David
Gloor, Susan L.
Vigers, Guy
Morales, Tony
Aliagas, Ignacio
Liu, Bonnie
Sideris, Steve
Hoeflich, Klaus
Jaiswal, Bijay S.
Seshagiri, Sonnasekar
Koeppen, Hartmut
Belvin, Marcia
Friedman, Lori S.
Malek, Shiva
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-5753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5753
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex
    Vasta, James D.
    Michaud, Ani
    Zimprich, Chad A.
    Beck, Michael T.
    Swiatnicki, Matthew R.
    Zegzouti, Hicham
    Thomas, Morgan R.
    Wilkinson, Jennifer
    Crapster, J. Aaron
    Robers, Matthew B.
    CELL CHEMICAL BIOLOGY, 2023, 30 (11) : 1354 - +
  • [22] Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK
    Zhang, P
    Wang, YZ
    Kagan, E
    Bonner, JC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (29) : 22479 - 22486
  • [23] Discovery of a kinome signature predicting sensitivity and resistance to RAF-MAPK pathway inhibitors in melanoma
    Hilhorst, Riet
    Krayem, Mohammed
    Van den Berg, Adrienne
    Journe, Fabrice
    Hovestad-Bijl, Liesbeth
    Van den Hooven, Tim
    de Wijn, Rik
    Aftimos, Philippe
    Ghanem, Ghanem
    Ruijtenbeek, Rob
    CANCER RESEARCH, 2017, 77
  • [24] Targeting the MAPK pathway in advanced BRAF wild-type melanoma
    Massa, R. C.
    Kirkwood, J. M.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 503 - 505
  • [25] Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis
    Ta, Lisa
    Tsai, Brandon L.
    Deng, Weixian
    Sha, Jihui
    Varuzhanyan, Grigor
    Tran, Wendy
    Wohlschlegel, James A.
    Carr-Ascher, Janai R.
    Witte, Owen N.
    ISCIENCE, 2023, 26 (12)
  • [26] Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
    Tkacik, Emre
    Li, Kunhua
    Gonzalez-Del Pino, Gonzalo
    Ha, Byung Hak
    Vinals, Javier
    Park, Eunyoung
    Beyett, Tyler S.
    Eck, Michael J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (05)
  • [27] Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling
    Liu, Longbin
    Lee, Matthew R.
    Kim, Joseph L.
    Whittington, Douglas A.
    Bregman, Howard
    Hua, Zihao
    Lewis, Richard T.
    Martin, Matthew W.
    Nishimura, Nobuko
    Potashman, Michele
    Yang, Kevin
    Yi, Shuyan
    Vaida, Karina R.
    Epstein, Linda F.
    Babij, Carol
    Fernando, Manory
    Carnahan, Josette
    Norman, Mark H.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (10) : 2215 - 2234
  • [28] Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
    Takezawa, Ken
    Okamoto, Isamu
    Yonesaka, Kimio
    Hatashita, Erina
    Yamada, Yuki
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    CANCER RESEARCH, 2009, 69 (16) : 6515 - 6521
  • [29] Inhibition of the Ras/Raf/MAPK-pathway in GIST: Therapeutic potential?
    Philipps, E. S.
    Muehlenberg, T.
    Simon, S.
    Ecken, S.
    Grabellus, F.
    Taeger, G.
    Schuler, M.
    Bauer, S.
    ONKOLOGIE, 2011, 34 : 235 - 235
  • [30] Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF
    Hechtman, Jaclyn F.
    Zehir, Ahmet
    Yaeger, Rona
    Wang, Lu
    Middha, Sumit
    Zheng, Tao
    Hyman, David M.
    Solit, David
    Arcila, Maria E.
    Borsu, Laetitia
    Shia, Jinru
    Vakiani, Efsevia
    Saltz, Leonard
    Ladanyi, Marc
    MOLECULAR CANCER RESEARCH, 2016, 14 (03) : 296 - 301
12345